ResMed (RMD) : Mondays money flow analysis of ResMed (RMD) indicates the selling of stock on the strength of price. The investors sold the stock on every rise as seen in the downtick transactions of $15 million. In comparison, the inflow of money on upticks was a meager $9.3 million. The dollar value of composite uptick trades minus the downtick trades was negative $5.71 million. The uptick to downtick ratio of 0.62 in the money flow shows weakness. The uptick block trades were valued at $3.75 million. The downtick transaction value was high at $9.48 million, which denotes distribution on strength. The uptick to downtick ratio of block trades was 0.4. Hence, the net money flow in the stock was negative ($5.73 million). ResMed (RMD) gained $0.15 at $70.57, a change of 0.21% over the previous days close.
Shares of ResMed Inc. rose by 0.04% in the last five trading days and 8.95% for the last 4 weeks. ResMed Inc. is up 22.17% in the last 3-month period. Year-to-Date the stock performance stands at 32.88%.
ResMed (NYSE:RMD): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $70.41 and $70.26 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $70.90. The buying momentum continued till the end and the stock did not give up its gains. It closed at $70.60, notching a gain of 0.26% for the day. The total traded volume was 829,593 . The stock had closed at $70.42 on the previous day.
In a related news,The officer (Chief Financial Officer) of Resmed Inc, Sandercock Brett sold 35,000 shares at $70.5 on August 11, 2016. The Insider selling transaction had a total value worth of $2,467,500. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
ResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.